Search research articles
Contact Us
Filters
Showing results (771-780 of 834) with videos related to
Page
of 84
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2014
The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer
J L Meisel, D M Hyman, K Garg, et al.
Gynecologic Oncology
|
July 27, 2021
Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy
Derman Basaran, Thomas Boerner, Jessa Suhner, et al.
Gynecologic Oncology
|
July 16, 2023
Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study
Tiffany Y Sia, Beryl L Manning-Geist, Sarah Ehmann, et al.
Gynecologic Oncology
|
January 22, 2020
A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer
Karen A Cadoo, Rachel N Grisham, Roisin E O'Cearbhaill, et al.
Gynecologic Oncology
|
February 22, 2023
Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial
Aaron M Praiss, Qin Zhou, Alexia Iasonos, et al.
Ophthalmology
|
July 16, 2017
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy
Jasmine H Francis, Larissa A Habib, David H Abramson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 1, 2024
A pre-operative scoring model to estimate the risk of blood transfusion over an ovarian cancer debulking surgery (BLOODS score): a Memorial Sloan Kettering Cancer Center Team Ovary study
Ryan M Kahn, Thomas Boerner, Michael Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 23, 1998
Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis
V J Palombella, E M Conner, J W Fuseler, et al.
Gynecologic Oncology
|
July 11, 2024
Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer
Sarah Andres, Lindsey Finch, Alexia Iasonos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 20, 2022
MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma
Beryl Manning-Geist, Sushmita Gordhandas, Ying L Liu, et al.
Page
of 84
Search research articles
Search
Showing results (771-780 of 834) with videos related to
Sort By:
Page
of 84
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2014
The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer
J L Meisel, D M Hyman, K Garg, et al.
Gynecologic Oncology
|
July 27, 2021
Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy
Derman Basaran, Thomas Boerner, Jessa Suhner, et al.
Gynecologic Oncology
|
July 16, 2023
Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study
Tiffany Y Sia, Beryl L Manning-Geist, Sarah Ehmann, et al.
Gynecologic Oncology
|
January 22, 2020
A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer
Karen A Cadoo, Rachel N Grisham, Roisin E O'Cearbhaill, et al.
Gynecologic Oncology
|
February 22, 2023
Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial
Aaron M Praiss, Qin Zhou, Alexia Iasonos, et al.
Ophthalmology
|
July 16, 2017
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy
Jasmine H Francis, Larissa A Habib, David H Abramson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 1, 2024
A pre-operative scoring model to estimate the risk of blood transfusion over an ovarian cancer debulking surgery (BLOODS score): a Memorial Sloan Kettering Cancer Center Team Ovary study
Ryan M Kahn, Thomas Boerner, Michael Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 23, 1998
Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis
V J Palombella, E M Conner, J W Fuseler, et al.
Gynecologic Oncology
|
July 11, 2024
Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer
Sarah Andres, Lindsey Finch, Alexia Iasonos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 20, 2022
MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma
Beryl Manning-Geist, Sushmita Gordhandas, Ying L Liu, et al.
Page
of 84